Surveillance/Follow-up, 2nd bullet revised:Mammogram every 12 mo (First mammogram 6-12 mo, after breast-conservation therapy,(category 2B)and annually thereafter 脚注p修改:他莫昔芬标准剂量为每天20毫克,持续5年。仅当患者服用20毫克剂量时有症状,或患者不愿意或...
Surveillance/Follow-up, 2nd bullet revised:Mammogram every 12 mo (First mammogram 6-12 mo, after breast-conservation therapy,(category 2B)and annually thereafter 脚注p修改:他莫昔芬标准剂量为每天20毫克,持续5年。仅当患者服用20毫克剂量时有症状,或患者不愿意或不能服用标准剂量他莫昔芬时,低剂量他莫...
Surveillance/Follow-up, 2nd bullet revised:Mammogram every 12 mo (First mammogram 6-12 mo, after breast-conservation therapy,(category 2B)and annually thereafter 脚注p修改:他莫昔芬标准剂量为每天20毫克,持续5年。仅当患者服用20毫克剂量时有症状,或患者不愿意或不能服用标准剂量他莫昔芬时,低剂量他莫...
General: Recommendations for Lobular Carcinoma in Situ (LCIS-1) were removed from the NCCN Guidelines for Breast Cancer; see the NCCN Guidelines for Breast Cancer Screening and Diagnosis. 导管原位癌的诊断、检查、基本治疗(DCIS-1) 修改:若患者遗传性乳腺癌风险高则进行遗传咨询 → 若患者有遗传性乳腺癌...
* Modified footnote "o" for consistency with NCCN Guidelines for Breast Cancer Risk Reduction. The footnote states "CYP2D6 genotype testing is not recommended in women who are considering tamoxifen." *为了与NCCN降低乳腺癌风险指南一致修改脚注“o”。脚注指出“在考虑他莫昔芬的女性中不建议CYP2D6基因...
General: Recommendations for Lobular Carcinoma in Situ (LCIS-1) were removed from the NCCN Guidelines for Breast Cancer; see the NCCN Guidelines for Breast Cancer Screening and Diagnosis. 导管原位癌的诊断、检查、基本治疗(DCIS-1) 修改:若患者遗传性乳腺癌风险高则进行遗传咨询 → 若患者有遗传性乳腺癌...
(BINV-N) Surveillance/Follow-Up, Recurrence Workup or Preferred Chemotherapy Regimens for Initial Workup for Stage lV Disease (BINV-16) Recurrent or Metastatic Breast Cancer (BINV-O) Treatment of Recurrence/Stage IV Disease Special Considerations (BINV-17) Phyllodes Tumor (PHYLL-1) Principles ...
Added pathway for LCIS based on surgical biopsy results. Recommend counseling regarding risk reduction and surveillance per NCCN Breast Cancer Risk Reduction Guidelines and NCCN Breast Cancer Screening and Diagnosis Guidelines. Modified footnote k: " ...
●The Discussion section has been updated to relect the changes in the algorithm. Updates in Version 2.2015 of the NCCN Guidelines for Breast Cancer from Version 1.2015 include: ●讨论部分已经更新为反映出工作步骤方面的变化。 2015年第2版乳腺癌NCCN指南从2015年第1版的更新包括: ...
The panel also revisited the NCCN Guidelines for surveillance after successful local therapy for esophageal and gastroesophageal junction cancers. The optimal surveillance strategy for these patients has remained controversial, with no high-level evidence to guide the development of algorithms that balance ...